Differential requirements of androgen receptor in luminal progenitors during prostate regeneration and tumor initiation

  1. Chee Wai Chua
  2. Nusrat J Epsi
  3. Eva Y Leung
  4. Shouhong Xuan
  5. Ming Lei
  6. Bo I Li
  7. Sarah K Bergren
  8. Hanina Hibshoosh
  9. Antonina Mitrofanova
  10. Michael M Shen  Is a corresponding author
  1. Columbia University Medical Center, United States
  2. Rutgers, The State University of New Jersey, United States

Abstract

Master regulatory genes of tissue specification play key roles in stem/progenitor cells and are often important in cancer. In the prostate, androgen receptor (AR) is a master regulator essential for development and tumorigenesis, but its specific functions in prostate stem/progenitor cells have not been elucidated. We have investigated AR function in CARNs (CAstration-Resistant Nkx3.1-expressing cells), a luminal stem/progenitor that functions in prostate regeneration. Using genetically-engineered mouse models and novel prostate epithelial cell lines, we find that progenitor properties of CARNs are largely unaffected by AR deletion, apart from decreased proliferation in vivo. Furthermore, AR loss suppresses tumor formation after deletion of the Pten tumor suppressor in CARNs; however, combined Pten deletion and activation of oncogenic Kras results in AR-negative tumors with focal neuroendocrine differentiation. Our findings show that AR modulates specific progenitor properties of CARNs, including their ability to serve as a cell of origin for prostate cancer.

Data availability

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Chee Wai Chua

    Department of Medicine, Columbia University Medical Center, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Nusrat J Epsi

    Department of Health Informatics, Rutgers, The State University of New Jersey, Newark, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5363-075X
  3. Eva Y Leung

    Department of Medicine, Columbia University Medical Center, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Shouhong Xuan

    Department of Medicine, Columbia University Medical Center, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Ming Lei

    Department of Medicine, Columbia University Medical Center, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Bo I Li

    Department of Medicine, Columbia University Medical Center, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Sarah K Bergren

    Department of Medicine, Columbia University Medical Center, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Hanina Hibshoosh

    Department of Pathology and Cell Biology, Columbia University Medical Center, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Antonina Mitrofanova

    Department of Health Informatics, Rutgers, The State University of New Jersey, Newark, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Michael M Shen

    Department of Medicine, Columbia University Medical Center, New York, United States
    For correspondence
    mshen@columbia.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4042-1657

Funding

National Institute of Diabetes and Digestive and Kidney Diseases (DK076602)

  • Michael M Shen

National Cancer Institute (CA1966692)

  • Michael M Shen

U.S. Department of Defense (Prostate Cancer Research Program PC101820)

  • Chee Wai Chua

U.S. Department of Defense (Prostate Cancer Research Program PC141064)

  • Bo I Li

Prostate Cancer Foundation

  • Michael M Shen

Rutgers SHP Dean's Intramural Grant

  • Antonina Mitrofanova

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All animal experiments were performed under protocol AAAR9408, which was approved by the Institutional Animal Care and Use Committee at Columbia University Medical Center.

Human subjects: Radical prostatectomy samples were obtained from consented patients under the auspices of an Institutional Review Board approved protocol AAAC4997 at Columbia University Medical Center.

Copyright

© 2018, Chua et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,125
    views
  • 530
    downloads
  • 25
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Chee Wai Chua
  2. Nusrat J Epsi
  3. Eva Y Leung
  4. Shouhong Xuan
  5. Ming Lei
  6. Bo I Li
  7. Sarah K Bergren
  8. Hanina Hibshoosh
  9. Antonina Mitrofanova
  10. Michael M Shen
(2018)
Differential requirements of androgen receptor in luminal progenitors during prostate regeneration and tumor initiation
eLife 7:e28768.
https://doi.org/10.7554/eLife.28768

Share this article

https://doi.org/10.7554/eLife.28768

Further reading

    1. Cancer Biology
    Qianqian Ju, Wenjing Sheng ... Cheng Sun
    Research Article

    TAK1 is a serine/threonine protein kinase that is a key regulator in a wide variety of cellular processes. However, the functions and mechanisms involved in cancer metastasis are still not well understood. Here, we found that TAK1 knockdown promoted esophageal squamous cancer carcinoma (ESCC) migration and invasion, whereas TAK1 overexpression resulted in the opposite outcome. These in vitro findings were recapitulated in vivo in a xenograft metastatic mouse model. Mechanistically, co-immunoprecipitation and mass spectrometry demonstrated that TAK1 interacted with phospholipase C epsilon 1 (PLCE1) and phosphorylated PLCE1 at serine 1060 (S1060). Functional studies revealed that phosphorylation at S1060 in PLCE1 resulted in decreased enzyme activity, leading to the repression of phosphatidylinositol 4,5-bisphosphate (PIP2) hydrolysis. As a result, the degradation products of PIP2 including diacylglycerol (DAG) and inositol IP3 were reduced, which thereby suppressed signal transduction in the axis of PKC/GSK-3β/β-Catenin. Consequently, expression of cancer metastasis-related genes was impeded by TAK1. Overall, our data indicate that TAK1 plays a negative role in ESCC metastasis, which depends on the TAK1-induced phosphorylation of PLCE1 at S1060.

    1. Cancer Biology
    2. Cell Biology
    Rui Hua, Jean X Jiang
    Insight

    Cell crowding causes high-grade breast cancer cells to become more invasive by activating a molecular switch that causes the cells to shrink and spread.